- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05932550
Safety of Maraviroc for Post-stroke Depression (MRV-PSD)
Safety of Maraviroc for Post-stroke Depression (Proof-of-concept)
Post-stroke depression (PSD) is a barrier to effective rehabilitation and recovery after stroke. Current treatment options are limited and there is an unmet need for specific and effective therapeutic options.
Objective: To examine the safety and efficacy of Maraviroc, a CCR5 antagonist, as a possible add-on treatment option for PSD, in an open-labeled proof-of-concept clinical trial.
Design, Setting, and Participants: A 10-week trial of daily oral 300 mg Maraviroc in ten patients with subcortical stroke suffering from PSD. Follow-up: eight weeks after completing treatment.
Main Outcome Measure: A change in the Montgomery-Asberg Depression Rating Scale (MADRS).
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Men and women aged 50 to 86 years;
- Able to fully comprehend and sign an informed consent form;
- Diagnosis of stroke/TIA prior to study entrance and evidence of ischemic infarct and/or lacunar infarcts on MRI (defined as sharply demarcated hypointense lesions <20mm on T1-weighted images with corresponding hypointense lesions with hyperintense rim on FLAIR) and/or deep Cerebral Microbleeds (CMB) (defined as round hypointense lesions on T2-weighted gradient echo-images with a diameter < 10 mm in neuroimaging.
- Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) diagnostic criteria for major depressive episode that developed up to 12 months after the documented stroke/TIA.
- Able to comply with scheduled visits, treatment plan, and other trial procedures;
Treatment with other antidepressants is allowed but subjects will be asked not to change their regular treatment regime during the trial.
Exclusion Criteria:
- Hemorrhages and cerebral edema (e.g., subarachnoid haemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma)
- Patients in a state of coma or with severe disturbance of consciousness, aphasia, agnosia, or deafness that subsequently affects expression and communication.
- Significant acute medical illness including: drug overdose, severely disturbed liver, kidney or lung function, anemia, hypothyroidism, or uncontrolled diabetes.
- Significant acute neurologic illness including: impaired consciousness, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, or severe aphasia
- Patients diagnosed with dementia or major neurocognitive disorder as defined by DSM-5at screening, or other neurological conditions that might dominate the clinical picture (multiple sclerosis, Parkinson's disease, epilepsy, Huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, etc.)
- Subject has a history of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or elevated hepatic transaminases or bilirubin, or tests positive for HIV at Screening.
- History of renal insufficiency or serum creatinine over 1.6;;
- Subject has a current or past diagnosis of bipolar or related disorders, intellectual disability, cluster B personality disorder (e.g., borderline personality disorder, antisocial personality disorder, histrionic personality disorder, and narcissistic personality disorder), psychotic disorder, schizophrenia, PTSD , and substance/alcohol use disorders other than nicotine in the past year (including barbiturates, methadone, opiates, cocaine, cannabinoids, and amphetamine/ methamphetamine).
- Subject has suicidal ideation with intent to act during the screening phase or on Day 1 per investigator's clinical judgment, or has a history of suicidal behavior within the past year; or subject has homicidal ideation/intent at Screening or on Day 1.
- Subject has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigatoris considered cured with minimal risk of recurrence).
- Subject has known allergies, hypersensitivity, intolerance, or contraindication to Maraviroc or its excipients.
- Subject has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 60 days before the planned first dose of study drug or is currently enrolled in an investigational study.
- Subject is a woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug.
- Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
- Subject has had major surgery, (e.g., requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.
- Use of drugs with possible interactions with Maraviroc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maraviroc 300 mg/day
Open-label study
|
10 week treatment as add-on therapy to anti-depressants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: 10 weeks
|
depression score
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
16-item quick inventory of depressive symptoms- self-report, QIDS-SR16
Time Frame: 10 weeks
|
self-report depression score
|
10 weeks
|
clinical global impression scale (CGI)
Time Frame: 10 weeks
|
Clinician impression
|
10 weeks
|
7-item patient-reported generalized anxiety disorder 7-item scale- GAD-7
Time Frame: 10 weeks
|
Anxiety score
|
10 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mood Disorders
- Stroke
- Depression
- Depressive Disorder
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Fusion Inhibitors
- Viral Fusion Protein Inhibitors
- CCR5 Receptor Antagonists
- Maraviroc
Other Study ID Numbers
- 0056-20-TLV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-stroke Depression
-
University of CincinnatiRecruitingPost-stroke DepressionUnited States
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingHealthy | Post-stroke DepressionChina
-
Chinese University of Hong KongResearch Grants Council, Hong KongRecruiting
-
Maastricht University Medical CenterCompletedVascular Dementia | Post-stroke Depression | Vascular Cognitive Impairment | Post-stroke Apathy | Post-stroke DementiaNetherlands
-
University Hospital of North NorwayNorwegian Extra Foundation for Health and RehabilitationCompletedStroke | Quality of Life | Fatigue | Cognitive Impairment | Post-stroke Depression | Neuropsychology | Post-Stroke Fatigue | Meta-cognitionNorway
-
University Medicine GreifswaldCompletedPost-stroke Depression | Post-stroke AphasiaGermany
-
Zhujiang HospitalUnknown
-
The Third Affiliated hospital of Zhejiang Chinese...Hangzhou Hospital of Traditional Chinese Medicine; Zhejiang General Hospital... and other collaboratorsRecruiting
-
Kibi International UniversityUnknown
-
Xuanwu Hospital, BeijingUnknownPost-stroke DepressionChina
Clinical Trials on Maraviroc 300 mg
-
Abramson Cancer Center of the University of PennsylvaniaCompletedHematopoietic Stem Cell Transplantation | Graft-versus-host Disease
-
University of California, Los AngelesTerminated
-
University Of PerugiaCompletedInflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other ConditionsItaly
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Completed
-
Hospital Universitario Infanta LeonorHospital Clinic of Barcelona; ViiV HealthcareTerminated
-
Bausch Health Americas, Inc.CompletedRheumatoid ArthritisUnited States
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisUnited States
-
Radboud University Medical CenterUnknownAcute Kidney Injury | Critically Ill ChildrenNetherlands
-
University of Turin, ItalyWithdrawn
-
King Abdullah International Medical Research CenterNovartisTerminatedMyeloid Leukemia, ChronicSaudi Arabia